Drug Trial Radar · NCT06966700
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,400
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Mar 23, 2033
Study completion Dec 29, 2034
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Conditions
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecanBiological
IV infusion
PembrolizumabBiological
IV infusion
Rescue MedicationDrug
Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
CarboplatinDrug
IV infusion
PaclitaxelDrug
IV infusion
DoxorubicinDrug
IV infusion
EpirubicinDrug
IV infusion
CyclophosphamideDrug
IV infusion
CapecitabineDrug
Oral tablet
OlaparibDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive SurgeryTime frame: Up to approximately 30 weeks
- Event-Free Survival (EFS)Time frame: Up to approximately 92 months
Locations
338 sites in 41 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0066)
Gilbert, Arizona · Recruiting
Mayo Clinic Cancer Center ( Site 0034)
Phoenix, Arizona · Recruiting
University of Arizona Cancer Center ( Site 0035)
Tucson, Arizona · Recruiting
Roy and Patricia Disney Family Cancer Center ( Site 0055)
Burbank, California · Recruiting
Community Cancer Institute ( Site 0100)
Clovis, California · Recruiting
Providence Medical Foundation ( Site 0080)
Fullerton, California · Recruiting
MemorialCare Health System - Long Beach Medical Center ( Site 9556)
Long Beach, California · Recruiting
El Camino Hospital Cancer Center ( Site 0096)
Mountain View, California · Recruiting
Hoag Memorial Hospital Presbyterian ( Site 0010)
Newport Beach, California · Recruiting
Helios Clinical Research ( Site 0061)
Whittier, California · Recruiting
Intermountain Health Cancer Center Saint Joseph ( Site 0062)
Denver, Colorado · Recruiting
Rocky Mountain Cancer Centers (RMCC) ( Site 8006)
Denver, Colorado · Recruiting
Intermountain Health St. Mary's Regional Hospital ( Site 0054)
Grand Junction, Colorado · Recruiting
AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044)
Altamonte Springs, Florida · Recruiting
Florida Cancer Specialists - South ( Site 7004)
Fort Myers, Florida · Recruiting
Bioresearch Partner ( Site 0072)
Hialeah, Florida · Recruiting
Mayo Clinic Hospital ( Site 0013)
Jacksonville, Florida · Recruiting
Florida Cancer Specialists - North ( Site 7002)
St. Petersburg, Florida · Recruiting
City of Hope Cancer Center - Atlanta ( Site 0102)
Newnan, Georgia · Recruiting
Southern Illinois Hospital Services ( Site 9554)
Carterville, Illinois · Recruiting
Fort Wayne Medical Oncology and Hematology ( Site 0084)
Fort Wayne, Indiana · Recruiting
Franciscan Health ( Site 0077)
Indianapolis, Indiana · Recruiting
Ochsner Clinic Foundation ( Site 0021)
New Orleans, Louisiana · Recruiting
Louisiana State University Health Sciences Shreveport ( Site 0053)
Shreveport, Louisiana · Recruiting
New England Cancer Specialists ( Site 0051)
Westbrook, Maine · Recruiting
Mercy Medical Center - Baltimore ( Site 0015)
Baltimore, Maryland · Recruiting
Massachusetts General Hospital Cancer Center ( Site 0091)
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute ( Site 0090)
Boston, Massachusetts · Recruiting
Saint Luke's Cancer Institute ( Site 0059)
Kansas City, Missouri · Recruiting
Washington University Siteman Cancer Center ( Site 0031)
St Louis, Missouri · Recruiting
Cancer Partners of Nebraska ( Site 0068)
Lincoln, Nebraska · Recruiting
Optum Care Cancer Center ( Site 0050)
Las Vegas, Nevada · Recruiting
Renown Regional Medical Center ( Site 0041)
Reno, Nevada · Recruiting
Hackensack Univ Medical Center (HUMC) ( Site 0007)
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey ( Site 0076)
New Brunswick, New Jersey · Recruiting
Altru Health System ( Site 0057)
Grand Forks, North Dakota · Recruiting
Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
Cincinnati, Ohio · Recruiting
Northwest Cancer Specialists (Compass Oncology) ( Site 8010)
Tigard, Oregon · Recruiting
Medical University of South Carolina-Hollings Cancer Center ( Site 0016)
Charleston, South Carolina · Recruiting
St Francis Cancer Center ( Site 0093)
Greenville, South Carolina · Recruiting
Showing 40 of 338 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.